Adenosine and stroke: Maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant

Rebecca L. Williams-Karnesky, Mary Stenzel-Poore

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Stroke is a leading cause of morbidity and mortality in the United States. Despite intensive research into the development of treatments that lessen the severity of cerebrovascular injury, no major therapies exist. Though the potential use of adenosine as a neuroprotective agent in the context of stroke has long been realized, there are currently no adenosine-based therapies for the treatment of cerebral ischemia and reperfusion. One of the major obstacles to developing adenosine-based therapies for the treatment of stroke is the prevalence of functional adenosine receptors outside the central nervous system. The activities of peripheral immune and vascular endothelial cells are particularly vulnerable to modulation via adenosine receptors. Many of the pathophysiological processes in stroke are a direct result of peripheral immune infiltration into the brain. Ischemic preconditioning, which can be induced by a number of stimuli, has emerged as a promising area of focus in the development of stroke therapeutics. Reprogramming of the brain and immune responses to adenosine signaling may be an underlying principle of tolerance to cerebral ischemia. Insight into the role of adenosine in various preconditioning paradigms may lead to new uses for adenosine as both an acute and prophylactic neuroprotectant.

Original languageEnglish (US)
Pages (from-to)217-227
Number of pages11
JournalCurrent Neuropharmacology
Volume7
Issue number3
DOIs
StatePublished - 2009

Fingerprint

Neuroprotective Agents
Adenosine
Stroke
Purinergic P1 Receptors
Brain Ischemia
Therapeutics
Ischemic Preconditioning
Brain
Reperfusion
Central Nervous System
Endothelial Cells
Morbidity
Mortality
Wounds and Injuries
Research

Keywords

  • Adenosine
  • Adenosine receptors
  • Cerebral ischemia
  • Neuroprotection
  • Preconditioning
  • Stroke
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Pharmacology
  • Neurology
  • Psychiatry and Mental health

Cite this

Adenosine and stroke : Maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant. / Williams-Karnesky, Rebecca L.; Stenzel-Poore, Mary.

In: Current Neuropharmacology, Vol. 7, No. 3, 2009, p. 217-227.

Research output: Contribution to journalArticle

@article{dc8386e6fdf749668ffa33966cf42d22,
title = "Adenosine and stroke: Maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant",
abstract = "Stroke is a leading cause of morbidity and mortality in the United States. Despite intensive research into the development of treatments that lessen the severity of cerebrovascular injury, no major therapies exist. Though the potential use of adenosine as a neuroprotective agent in the context of stroke has long been realized, there are currently no adenosine-based therapies for the treatment of cerebral ischemia and reperfusion. One of the major obstacles to developing adenosine-based therapies for the treatment of stroke is the prevalence of functional adenosine receptors outside the central nervous system. The activities of peripheral immune and vascular endothelial cells are particularly vulnerable to modulation via adenosine receptors. Many of the pathophysiological processes in stroke are a direct result of peripheral immune infiltration into the brain. Ischemic preconditioning, which can be induced by a number of stimuli, has emerged as a promising area of focus in the development of stroke therapeutics. Reprogramming of the brain and immune responses to adenosine signaling may be an underlying principle of tolerance to cerebral ischemia. Insight into the role of adenosine in various preconditioning paradigms may lead to new uses for adenosine as both an acute and prophylactic neuroprotectant.",
keywords = "Adenosine, Adenosine receptors, Cerebral ischemia, Neuroprotection, Preconditioning, Stroke, Treatment",
author = "Williams-Karnesky, {Rebecca L.} and Mary Stenzel-Poore",
year = "2009",
doi = "10.2174/157015909789152209",
language = "English (US)",
volume = "7",
pages = "217--227",
journal = "Current Neuropharmacology",
issn = "1570-159X",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Adenosine and stroke

T2 - Maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant

AU - Williams-Karnesky, Rebecca L.

AU - Stenzel-Poore, Mary

PY - 2009

Y1 - 2009

N2 - Stroke is a leading cause of morbidity and mortality in the United States. Despite intensive research into the development of treatments that lessen the severity of cerebrovascular injury, no major therapies exist. Though the potential use of adenosine as a neuroprotective agent in the context of stroke has long been realized, there are currently no adenosine-based therapies for the treatment of cerebral ischemia and reperfusion. One of the major obstacles to developing adenosine-based therapies for the treatment of stroke is the prevalence of functional adenosine receptors outside the central nervous system. The activities of peripheral immune and vascular endothelial cells are particularly vulnerable to modulation via adenosine receptors. Many of the pathophysiological processes in stroke are a direct result of peripheral immune infiltration into the brain. Ischemic preconditioning, which can be induced by a number of stimuli, has emerged as a promising area of focus in the development of stroke therapeutics. Reprogramming of the brain and immune responses to adenosine signaling may be an underlying principle of tolerance to cerebral ischemia. Insight into the role of adenosine in various preconditioning paradigms may lead to new uses for adenosine as both an acute and prophylactic neuroprotectant.

AB - Stroke is a leading cause of morbidity and mortality in the United States. Despite intensive research into the development of treatments that lessen the severity of cerebrovascular injury, no major therapies exist. Though the potential use of adenosine as a neuroprotective agent in the context of stroke has long been realized, there are currently no adenosine-based therapies for the treatment of cerebral ischemia and reperfusion. One of the major obstacles to developing adenosine-based therapies for the treatment of stroke is the prevalence of functional adenosine receptors outside the central nervous system. The activities of peripheral immune and vascular endothelial cells are particularly vulnerable to modulation via adenosine receptors. Many of the pathophysiological processes in stroke are a direct result of peripheral immune infiltration into the brain. Ischemic preconditioning, which can be induced by a number of stimuli, has emerged as a promising area of focus in the development of stroke therapeutics. Reprogramming of the brain and immune responses to adenosine signaling may be an underlying principle of tolerance to cerebral ischemia. Insight into the role of adenosine in various preconditioning paradigms may lead to new uses for adenosine as both an acute and prophylactic neuroprotectant.

KW - Adenosine

KW - Adenosine receptors

KW - Cerebral ischemia

KW - Neuroprotection

KW - Preconditioning

KW - Stroke

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=70349696212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349696212&partnerID=8YFLogxK

U2 - 10.2174/157015909789152209

DO - 10.2174/157015909789152209

M3 - Article

C2 - 20190963

AN - SCOPUS:70349696212

VL - 7

SP - 217

EP - 227

JO - Current Neuropharmacology

JF - Current Neuropharmacology

SN - 1570-159X

IS - 3

ER -